Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma

Table 1 Characteristics of the 97 postmenopausal patients with estrogen receptor alpha-positive breast tumors and relation to relapse-free survival

		Relapse-free survival
	Number of patients	Relapses (%)	P ^a
Age
≤ 70 years	47	18 (40.0)	NS (0.89)
> 70 years	50	14 (26.5)
Histological grade^b,c
I + II	77	20 (26.0)	0.0057
III	19	11 (57.9)
Lymph node status
0	16	1 (6.2)	0.0018
1–3	52	15 (28.8)
> 3	29	16 (55.2)
Macroscopic tumor size^c
≤ 30 mm	66	18 (27.3)	0.028
> 30 mm	30	14 (46.7)
Estrogen receptor alpha RNA status
Low	33	16 (48.5)	NS (0.078)
Intermediate	32	6 (18.8)
High	32	10 (31.2)
Estrogen receptor beta RNA status
Low	33	5 (15.1)	NS (0.062)
Intermediate	32	14 (43.8)
High	32	13 (40.6)

^a P value, log-rank test. NS, not significant. ^b Scarff Bloom Richardson classification. ^c Information available for 96 patients.

ISSN: 1465-542X